Home-Based Cancer Symptom Management

描述(申请人提供)：由于疾病进展或癌症治疗引起的副作用而引起的癌症症状很普遍。大多数癌症患者在门诊接受治疗，不得不在家里自我管理这些症状。由于各种原因，患者及其照顾者的症状自我管理可能会给自己带来巨大负担，导致不必要的住院或诊所就诊导致患者预后不佳，并增加医疗成本。该项目的目标是开发一个基于家庭的癌症症状管理(CSM)系统，以促进患者对癌症症状和治疗副作用的自我管理，并促进护理团队的远程管理。预期的好处包括改善患者自我报告的结果，更好的自我效能，更好的患者与提供者的沟通，以及减少住院/诊所就诊。这是一个快速跟踪应用程序。我们的第一阶段目标包括：1)通过焦点小组和访谈收集和分析系统需求；2)通过迭代的以用户为中心的设计和面向对象的软件开发方法设计和开发工作原型；以及3)通过小规模试点测试评估系统的可用性和用户接受性。我们的第二阶段目标包括：1)通过增加多媒体患者教育内容并通过彻底检查系统架构级别的问题(如性能、可扩展性和可维护性)来开发最终产品；以及2)在两个临床地点进行更大规模的随机对照试验，以评估我们症状管理解决方案的有效性。

DESCRIPTION (provided by applicant): Cancer symptoms due to disease progression or side effects caused by cancer treatment are prevalent. Most cancer patients are treated in outpatient settings, having to self-manage these symptoms at home. For a variety of reasons, symptom self-management by patients and their caregivers can be a tremendous burden on themselves, resulting in suboptimal patient outcomes and increased healthcare costs due to unnecessary hospitalizations or clinic visits. The goal of this project is to develop a home-based Cancer Symptom Management (CSM) system to promote patient self-management of cancer symptoms and treatment side effects and facilitate remote management by the care team. The anticipated benefits include improved patient self-reported outcomes, better self-efficacy, better patient-provider communication, and reduced hospital stays/clinic visits. This is a Fast Track application. Our Phase I aims include: 1) the collection and analysis of system requirements via focus groups and interviews; 2) the design and development of a working prototype via iterative user- centric design and object-oriented software development methodologies; and 3) the evaluation of system usability and user acceptance via a small-scale pilot test. Our Phase II aims include: 1) the development of the final product by adding multimedia patient education contents and by thoroughly examining system architecture level issues such as performance, scalability, and maintainability; and 2) a larger-scale randomized controlled trial at two clinical sites to evaluate the efficacy of our symptom management solution.